Would you re-test tirzepatide after ten weeks at 2–8 °C, or accept the original certificate?

The specifics, since they change the answer: tirzepatide · ten weeks · 2–8 °C.

I would like to define my thresholds before I have a result, for obvious reasons.

I want a plan with explicit stopping rules, not just steps.

What is the minimum version of this that is still defensible?

ten weeks is 70 days, and at 2–8 °C the ten-degree rule of thumb makes that roughly 70 refrigerated days of equivalent exposure. 2–8 °C is the condition the rule of thumb is anchored to, so it is the baseline rather than a multiplier: everything else in this thread is quoted relative to it. Compare that against what the certificate covers, which is the material as it left the laboratory on the date of analysis and nothing after it. That is short enough that a re-test is a stability study rather than a safety check — worth doing if you will publish the result, hard to justify if you will only reassure yourself. If you do re-test, send it for content as well as purity; the 70 days will have moved one of them further than the other.

Concretely, batch testing establishes what can be claimed about the lot as a whole, and the sample size determines how much you can actually claim.

If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

The practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.

Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.

Specifically, if the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

Assume segregation is possible, and design your sampling to catch it if it exists.

edited 20 Aug 2026 by rukhsana_iqbal — added a caveat about sampling

Worth being precise here: if a lot has visibly segregated — some vials showing different appearance — then sampling the top and bottom of the shipment is worth doing.

The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

On the detail: for a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.

If testing multiple vials, state how many you tested and why you chose those vials.

The honest statement is that unless you have tested multiple vials or have segregation data, you are making an assumption about lot homogeneity that may not hold.

A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.

The ICH Q3A and Q3B thresholds for reporting, identification and qualification of impurities are the framework the pharmaceutical industry works to, and they are worth reading even though nothing in the research-grade supply chain is obliged to meet them, because they tell you which numbers a competent analyst would consider worth reporting at all.

I would treat a "complies with" statement without sampling details as a claim rather than as evidence.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

Put another way, sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.

Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.

The relevant pharmacopoeial reference points here are the general chapters on peptide purity and on bacterial endotoxins; both specify method validation requirements that research-grade certificates almost never claim to meet, and the absence of that claim is itself information.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.